Mineralys Therapeutics Provides Corporate Update and Announces Participation in Upcoming LifeSci Partners Corporate Access Event in January 2026

Core Insights - Mineralys Therapeutics, Inc. is focused on developing treatments for hypertension and related comorbidities, with a significant emphasis on its drug candidate lorundrostat, which has shown promising results in clinical trials [1][8] Recent Clinical Highlights and Upcoming Milestones - The company has completed four successful clinical trials for lorundrostat, demonstrating its efficacy and safety profile, particularly in patients with uncontrolled hypertension (uHTN) and resistant hypertension (rHTN) [5] - The Phase 2 Explore-OSA trial is set to report topline results in Q1 2026, evaluating lorundrostat's effects on obstructive sleep apnea (OSA) and blood pressure [7] - An NDA for lorundrostat was submitted to the FDA in late 2025, following three positive clinical trials that highlighted its safety and 24-hour blood pressure control [7] - The ongoing Transform-HTN open-label extension trial allows participants to continue receiving lorundrostat, providing additional long-term safety and efficacy data [7] About Lorundrostat - Lorundrostat is a proprietary, orally administered aldosterone synthase inhibitor designed to treat uHTN, rHTN, chronic kidney disease (CKD), and OSA, with a 374-fold selectivity for aldosterone-synthase inhibition over cortisol-synthase [4][8] - The drug has demonstrated a 40-70% reduction in plasma aldosterone concentration in hypertensive participants, with a half-life of 10-12 hours [4] Company Overview - Mineralys Therapeutics is based in Radnor, Pennsylvania, and was founded by Catalys Pacific, focusing on innovative treatments for hypertension and related conditions [8]